The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

The Food and Drug Administration (FDA) approved the first-ever RSV vaccine, called Arexvy, for adults age 60 and older, in May. On its heels came another vaccine for adults 60+, called Abrysvo. Summer ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

Arexvy is approved for individuals aged 50 and older, while Abrysvo and mResvia are approved for those aged 60 and older. Additionally, Abrysvo is approved for use in people aged 18 to 59 who are at ...